Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rHuEPO · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| rHuEPO | ACTIVE_COMPARATOR | - |
| Darbepoetin alfa | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| rHuEPO | DRUG | rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12. |
| Darbepoetin alfa | DRUG | 4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11. |
Inclusion Criteria: * Subjects with non-myeloid malignancies planning to receive cyclic chemotherapy for 8 additional weeks or more * Anemia (hemoglobin \[hgb\] greater than or equal to 9.0g/dL and less than or equal to 11.0 g/dL) related to cancer and chemotherapy * Karnofsky performance status of...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
rHuEPO is an investigational therapy studied for patients with cancer, specifically those with non-myeloid malignancies who are receiving chemotherapy. It has been evaluated in a Phase 3 clinical trial in this patient population. It is not described as an approved treatment in the available information.
rHuEPO is being developed by Amgen Inc., which trades on the Nasdaq under the ticker AMGN. Amgen is the sponsor associated with the clinical development program for this asset in oncology.
rHuEPO is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently listed as active. The program has enrolled 718 patients in total across its clinical studies.
rHuEPO has been evaluated in the Phase 3 trial NCT00111137, titled Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy. That trial is completed and enrolled 718 patients. It was randomized and used an active control design, and participants were adults aged 18 years and older.
rHuEPO is described as being in Phase 3 clinical development, which means it remains investigational. The available information does not indicate that it has received FDA approval for the cancer indication studied. Development status should be confirmed through regulatory filings and the sponsor.